Estimated liver fibrosis and its impact on all-cause mortality of HCV Monoinfected and HCV/HIV-coinfected drug users

Current HIV Research

Volumn 9, Issue 4, 2011, Pages 256-262

  Sanvisens, A ^a   Fuster, D ^a   Serra, I ^a   Tor, J ^a   Tural, C ^a   Rey Joly, C ^a   Muga, R ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Chronic hepatitis C; HIV infection; Liver fibrosis; Mortality; Non invasive index

Indexed keywords

ALCOHOL; COCAINE; OPIATE;

ADULT; ALCOHOLISM; ALL CAUSE MORTALITY; ARTICLE; BLOOD SAMPLING; COCAINE DEPENDENCE; CONTROLLED STUDY; DEATH CERTIFICATE; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; FIB-4; FOLLOW UP; FORNS INDEX; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIXED INFECTION; MORTALITY; OPIATE ADDICTION; POHL SCORE; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SEROLOGY; VIRUS DETECTION;

EID: 79959922323     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211796320298     Document Type: Article

References (38)

1. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000; 284: 450-456.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl): S6-S9.
3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
4. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
5. Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 2008; 48: 657-665.
6. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33: 562-569.
7. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008.
8. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-217.
9. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
10. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 2002; 36(5 Suppl 1): S161-S172.
11. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-179.
12. Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-798.
13. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36(4 Pt 1): 986-992.
14. Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43: 78-84.
15. Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-279.
16. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-3146.
17. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
19. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006; 55: 409-414.
20. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40: 538-544.
21. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study--ANRS HC02. J Hepatol 2008; 48: 765-773.
22. Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis 2011; 52: 674-680.
23. th Conference on Retroviruses and Opportunistic Infections. Denver, USA, 2006.
24. Fuster D, Sanvisens A, Martinez E, et al. Predictors of increasing FIB-4 values in HCV monoinfected and HCV/HIV coinfected patients. 5th International Workshop on HIV & Hepatitis Co-Infection. Lisbon, Portugal, 2009.
25. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-1353.
26. Muga R, Roca J, Egea JM, et al. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000; 23: 332-338.
27. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: Prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15: 165-172.
28. Mendeni M, Foca E, Gotti D, et al. Evaluation of liver fibrosis: Concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis 2011; 52: 1164-1173.
29. Singal AG, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther 2011; 33: 566-577.
30. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53: 238-244.
31. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. the multivirc group. Hepatology 1999; 30: 1054-1058.
32. Fuster D, Planas R, Muga R, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20: 1293-1297.
33. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10: 118-125.
34. Harris HE, Ramsay ME, Andrews N, Eldridge KP, HCV National Register Steering Group. Hepatitis C virus. Clinical course of hepatitis C virus during the first decade of infection: Cohort study. BMJ 2002; 324: 450-453.
35. Wilson LE, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006; 43: 788-795.
36. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44: 463-469.
37. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29: 590-6.
38. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15: 212-218.